LYEL - Why Lyell Immunopharma Shares Are Rising Today | Benzinga
Lyell Immunopharma, Inc. (NASDAQ: LYEL) shares are trading higher after the company announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845 for the treatment of patients with stage IIB-IV melanoma.
LYL845 is an investigational tumor infiltrating lymphocyte (TIL) product candidate that is enhanced with Lyell's Epi-R manufacturing protocols.
It is currently being investigated in a ...